Baseline disease characteristics stratified by allele burden
| . | Total . | JAK2V617F allele burden . | P* . | ||||
|---|---|---|---|---|---|---|---|
| Negative . | >0%-25% . | 25%-50% . | 50%-75% . | >75% . | |||
| . | N = 536 . | n = 80 . | n = 132 . | n = 124 . | n = 79 . | n = 121 . | |
| Diagnosis, n (%) | <.0001 | ||||||
| PMF | 339 (63.2) | 61 (76.3) | 103 (78.0) | 102 (82.3) | 32 (40.5) | 41 (33.9) | |
| PPV-MF | 125 (23.3) | 1 (1.3) | 12 (9.1) | 10 (8.1) | 36 (45.6) | 66 (54.5) | |
| PET-MF | 71 (13.2) | 17 (21.3) | 17 (12.9) | 12 (9.7) | 11 (13.9) | 14 (11.6) | |
| DIPSS risk category, n (%) | .4281 | ||||||
| Intemediate-1 | 210 (39.2) | 26 (32.5) | 45 (34.1) | 46 (37.1) | 39 (49.4) | 54 (44.6) | |
| Intermediate-2 | 214 (39.9) | 36 (45.0) | 58 (43.9) | 48 (38.7) | 30 (38.0) | 42 (34.7) | |
| High | 111 (20.7) | 17 (21.3) | 29 (22.0) | 30 (24.2) | 10 (12.7) | 25 (20.7) | |
| Time since MF diagnosis, median (IQR), y | 1.5 (0.3-5) | 2.2 (0.4-5.6) | 1.3 (0.2-4.6) | 1.8 (0.5-5.2) | 2 (0.2-5) | 1.2 (0.2-3.7) | .3109 |
| Prior JAKi exposure, n (%) (PERSIST-2 only) | 98/216 (45.4) | 13/23 (46.4) | 21/69 (30.4) | 26/50 (52.0) | 13/29 (44.8) | 25/40 (62.5) | .0023† |
| Spleen volume, median (IQR), cm3 | 2196 (1454-3240) | 1816.8 (1271-2782) | 1642 (1187- 2598) | 2252 (1569-3360) | 2355.1 (1705-3246) | 2815.1 (1900-3818) | <.0001 |
| TSS score, n (IQR) | 21.6 (15.3-32.4) | 18.4 (14.4-33) | 21.14 (14.9-29.7) | 23.5 (18.8-31.8) | 21.57 (14.1-32.6) | 23 (15.7-36.4) | .2875 |
| Hemoglobin, median (IQR), g/dL | 10.1 (8.6-11.8) | 9.6 (8.6-11.0) | 9.6 (8.4-10.8) | 10.0 (8.3-11.3) | 10.4 (8.7-12.8) | 11.4 (9.7-13.2) | <.0001 |
| Platelet count, median (IQR), ×109/L | 92 (45-220) | 97 (41-187) | 83 (46-184) | 70 (34-171) | 118 (53-260) | 146 (60-364) | .0004 |
| RBC transfusion dependence, n (%) | 94 (17.5) | 18 (22.5) | 30 (22.7) | 27 (21.8) | 9 (11.4) | 10 (8.3) | .0005 |
| Platelet transfusion dependence, n (%) | 26 (4.9) | 5 (6.3) | 8 (6.1) | 7 (5.6) | 5 (6.3) | 1 (0.8) | .0623 |
| Blast percentage, median (IQR) | 1.6 (0-4) | 2 (0-4) | 1 (0-4) | 1.8 (0.7-4) | 1 (1-4) | 1.9 (0.4-4) | .4212 |
| Reticulin and collagen fibrosis staging, n (%) | .1077 | ||||||
| MF-0 | 17 (3.2) | 3 (3.8) | 6 (4.5) | 4 (3.3) | 1 (1.3) | 3 (2.5) | |
| MF-1 | 54 (10.1) | 12 (15.0) | 12 (9.1) | 11 (8.9) | 9 (11.5) | 10 (8.3) | |
| MF-2 | 185 (34.7) | 26 (32.5) | 43 (32.6) | 38 (30.9) | 25 (32.1) | 53 (44.2) | |
| MF-3 | 252 (47.3) | 35 (43.8) | 65 (49.2) | 66 (53.7) | 39 (50.0) | 47 (39.2) | |
| Missing | 25 (4.7) | 4 (5.0) | 6 (4.5) | 4 (3.3) | 4 (5.1) | 7 (5.8) | |
| Bone marrow cellularity, n (%) | .0519 | ||||||
| Hypocellular (<20%) | 103 (19.3) | 25 (31.3) | 29 (22.0) | 23 (18.7) | 9 (11.5) | 17 (14.2) | |
| Normocellular (20%-40%) | 57 (10.7) | 16 (20.0) | 15 (11.4) | 15 (12.2) | 5 (6.4) | 6 (5.0) | |
| Hypercellular (41%-100%) | 316 (59.3) | 33 (41.3) | 74 (56.1) | 71 (57.7) | 53 (67.9) | 85 (70.8) | |
| Unknown‡ | 57 (10.6) | 6 (7.5) | 14 (10.6) | 14 (11.3) | 11 (13.9) | 12 (9.9) | |
| . | Total . | JAK2V617F allele burden . | P* . | ||||
|---|---|---|---|---|---|---|---|
| Negative . | >0%-25% . | 25%-50% . | 50%-75% . | >75% . | |||
| . | N = 536 . | n = 80 . | n = 132 . | n = 124 . | n = 79 . | n = 121 . | |
| Diagnosis, n (%) | <.0001 | ||||||
| PMF | 339 (63.2) | 61 (76.3) | 103 (78.0) | 102 (82.3) | 32 (40.5) | 41 (33.9) | |
| PPV-MF | 125 (23.3) | 1 (1.3) | 12 (9.1) | 10 (8.1) | 36 (45.6) | 66 (54.5) | |
| PET-MF | 71 (13.2) | 17 (21.3) | 17 (12.9) | 12 (9.7) | 11 (13.9) | 14 (11.6) | |
| DIPSS risk category, n (%) | .4281 | ||||||
| Intemediate-1 | 210 (39.2) | 26 (32.5) | 45 (34.1) | 46 (37.1) | 39 (49.4) | 54 (44.6) | |
| Intermediate-2 | 214 (39.9) | 36 (45.0) | 58 (43.9) | 48 (38.7) | 30 (38.0) | 42 (34.7) | |
| High | 111 (20.7) | 17 (21.3) | 29 (22.0) | 30 (24.2) | 10 (12.7) | 25 (20.7) | |
| Time since MF diagnosis, median (IQR), y | 1.5 (0.3-5) | 2.2 (0.4-5.6) | 1.3 (0.2-4.6) | 1.8 (0.5-5.2) | 2 (0.2-5) | 1.2 (0.2-3.7) | .3109 |
| Prior JAKi exposure, n (%) (PERSIST-2 only) | 98/216 (45.4) | 13/23 (46.4) | 21/69 (30.4) | 26/50 (52.0) | 13/29 (44.8) | 25/40 (62.5) | .0023† |
| Spleen volume, median (IQR), cm3 | 2196 (1454-3240) | 1816.8 (1271-2782) | 1642 (1187- 2598) | 2252 (1569-3360) | 2355.1 (1705-3246) | 2815.1 (1900-3818) | <.0001 |
| TSS score, n (IQR) | 21.6 (15.3-32.4) | 18.4 (14.4-33) | 21.14 (14.9-29.7) | 23.5 (18.8-31.8) | 21.57 (14.1-32.6) | 23 (15.7-36.4) | .2875 |
| Hemoglobin, median (IQR), g/dL | 10.1 (8.6-11.8) | 9.6 (8.6-11.0) | 9.6 (8.4-10.8) | 10.0 (8.3-11.3) | 10.4 (8.7-12.8) | 11.4 (9.7-13.2) | <.0001 |
| Platelet count, median (IQR), ×109/L | 92 (45-220) | 97 (41-187) | 83 (46-184) | 70 (34-171) | 118 (53-260) | 146 (60-364) | .0004 |
| RBC transfusion dependence, n (%) | 94 (17.5) | 18 (22.5) | 30 (22.7) | 27 (21.8) | 9 (11.4) | 10 (8.3) | .0005 |
| Platelet transfusion dependence, n (%) | 26 (4.9) | 5 (6.3) | 8 (6.1) | 7 (5.6) | 5 (6.3) | 1 (0.8) | .0623 |
| Blast percentage, median (IQR) | 1.6 (0-4) | 2 (0-4) | 1 (0-4) | 1.8 (0.7-4) | 1 (1-4) | 1.9 (0.4-4) | .4212 |
| Reticulin and collagen fibrosis staging, n (%) | .1077 | ||||||
| MF-0 | 17 (3.2) | 3 (3.8) | 6 (4.5) | 4 (3.3) | 1 (1.3) | 3 (2.5) | |
| MF-1 | 54 (10.1) | 12 (15.0) | 12 (9.1) | 11 (8.9) | 9 (11.5) | 10 (8.3) | |
| MF-2 | 185 (34.7) | 26 (32.5) | 43 (32.6) | 38 (30.9) | 25 (32.1) | 53 (44.2) | |
| MF-3 | 252 (47.3) | 35 (43.8) | 65 (49.2) | 66 (53.7) | 39 (50.0) | 47 (39.2) | |
| Missing | 25 (4.7) | 4 (5.0) | 6 (4.5) | 4 (3.3) | 4 (5.1) | 7 (5.8) | |
| Bone marrow cellularity, n (%) | .0519 | ||||||
| Hypocellular (<20%) | 103 (19.3) | 25 (31.3) | 29 (22.0) | 23 (18.7) | 9 (11.5) | 17 (14.2) | |
| Normocellular (20%-40%) | 57 (10.7) | 16 (20.0) | 15 (11.4) | 15 (12.2) | 5 (6.4) | 6 (5.0) | |
| Hypercellular (41%-100%) | 316 (59.3) | 33 (41.3) | 74 (56.1) | 71 (57.7) | 53 (67.9) | 85 (70.8) | |
| Unknown‡ | 57 (10.6) | 6 (7.5) | 14 (10.6) | 14 (11.3) | 11 (13.9) | 12 (9.9) | |
IQR, interquartile range; JAKi, JAK inhibitor; PET-MF, post-ET MF; PPV-MF, post-PV MF; RBC, red blood cell.
P values to test the trend of continuous and ordinal variables were calculated with use of Jonckheere-Terpstra test and the trend of categorical variables were calculated using the Cochran-Armitage trend.
The P value represents the trend among patients only in PERSIST-2 as PERSIST-1 excluded prior JAK inhibitor therapy.
Unknown includes patients with missing bone marrow biopsy specimens or samples where cellularity could not be assessed.